Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,854 total articles
Lumentum (LITE) has been one of 2026’s breakout beneficiaries of the AI infrastructure cycle. After a steep run and a recent pullback from a May high, the stock is offering a tradeable setup: enter on signs of momentum resumption, use a disciplined stop under technical support, and target the prior 52-week high while monitoring valuation and custom…
Retail chatter suggests Meta is overextended, but the company’s advertising ARPU and cash flow profile argue for a tactical long. Valuation is reasonable relative to cash flow and profitability; a measured long with a tight stop can capture re-rating if AI-driven ARPU momentum continues.
Micron's stock is pricing a lot of the AI upside, but underlying fundamentals and industry supply dynamics still leave room for a continued move higher. Strong Q2 revenue prints, robust free cash flow, and low leverage give Micron the balance-sheet durability to capture AI-driven demand for HBM, DRAM, and NAND. Technical momentum and low days-to-co…
The Joint Corp. (JYNT) is actively shrinking its corporate footprint and accelerating refranchising. With a market cap of roughly $129M, low net debt, positive free cash flow and a franchise model that scales, the stock offers asymmetric upside if management executes. This trade idea lays out an actionable long with entry, stop and target, the rati…
Ford has momentum from a new Ford Energy unit and cost actions, but fundamentals and technicals suggest recent gains leave limited upside versus risk. My trade: wait for a pullback to $12.00 (roughly a 5% dividend yield), place a disciplined stop at $11.00, and target $15.00 over a long-term (180 trading days) holding period. That entry offers a fa…
Nvidia remains the dominant AI infrastructure provider with a market cap north of $5 trillion, strong free cash flow and expanding product scope into CPUs. Valuation looks rich but earnings momentum and product catalysts justify a tactical long. Trade plan: enter at $218.13, stop $195.00, target $270.00 over a mid-term (45 trading days) horizon.
Arqit (ARQQ) is a speculative long with a clear path to a turnaround: recent telecom and DoD wins plus a Vodafone partnership create a plausible revenue cadence that can re-rate the stock from its $256M market cap. I upgrade my rating and recommend a long trade with defined entry, stop and target.
Nvidia looks set for another leg higher if it clears the near-term technical hurdles. Fundamentals remain stellar and fresh product/cpu catalysts create a clear path; this trade spells out an entry at $220, stop at $205 and a $245 target over a mid-term (45 trading days) horizon.
Amgen combines strong free cash flow, a durable dividend, and growing exposure to high-growth modalities (oligonucleotides and cardiovascular indications). At $338, the stock offers a risk/reward setup into clear near-term and medium-term catalysts while valuation metrics remain reasonable for a cash-rich biotech. Long-term (180 trading days) trade…
Dine Brands trades at a subdued market cap below $400M despite steady free cash flow, low EV/EBITDA, and a dividend that screens high. Technical momentum and a growing push into dual-branded restaurants give a window for a mid-term long trade. Headline risk (franchise litigation, execution on dual-brands) and elevated short interest argue for a def…
Amazon has pushed back toward its 52-week high after a strong run; fundamentals — notably AWS growth, advertising strength and new AI/quantum initiatives — support further upside. Valuation at ~31x earnings and an enterprise value near $2.88T is reasonable given operating profit concentration in high-margin cloud. This trade idea lays out an entry …
Amazon is no longer just a volume play. With AWS delivering high, sustainable operating margins and advertising scaling, the investment case now rests on margin expansion and rising EPS. This trade idea targets a long position to ride multiple expansion as margins continue to outpace top-line growth.
Amtech (ASYS) is a small-cap equipment and materials player that has ripped higher from its 52-week low of $3.85 to the mid-$20s on improving fundamentals and momentum. The company carries a stretched valuation today (market cap ~$328M, P/E ~130x) but also generates positive free cash flow and sits on an enterprise value of roughly $296M. This trad…
Fluor (FLR) has a clear path to higher free cash flow and shareholder returns after monetizing its NuScale stake. With a $25.7B backlog, $1.4B buyback authorization and roughly $2.4B of proceeds earmarked for balance-sheet repair, this is a tactical buy-the-dip trade that pairs liquidity-driven upside with manageable execution risk.
Micron's stock has already priced in a huge rerating, but the underlying fundamentals - a Q2 revenue surge to $23.8B, $10.3B in free cash flow, and structural memory shortages for AI data centers - give a clear tactical setup. Use a mid-term (45 trading days) swing trade to ride continued AI spending while protecting capital on a clear stop.
Ferrari (RACE) has pulled back into the $340s after a volatile stretch. The brand's pricing power, high margins and order backlog give the stock a structural floor; the technicals and short interest suggest a tactical long trade with clearly defined entry, stop and target. I recommend a mid-term buy with a 45-trading-day horizon and tight risk mana…
Rocket Lab's rally is more than momentum: Q1 revenue of $200.3M (up 63.5% YoY), a record $2.2B backlog and a $90M Space Force contract make a compelling growth story. The stock is richly valued at a ~$78.6B market cap, so this trade is a tactical, mid-term long with strict risk controls: enter $140.00, target $170.00, stop $125.00, horizon ~45 trad…
Nebius is a high-growth AI infrastructure operator whose recent top-line acceleration and healthy adjusted EBITDA margin argue for material upside, even after a strong rally. The trade below buys into durable demand and improving unit economics while keeping a disciplined stop to respect execution and valuation risk.
Nvidia delivered another head-turning quarter, but the stock is priced for perfection. With a market cap north of $5 trillion, a P/E near 33 and P/S above 20, a modest miss in guidance or stretched margin assumptions could trigger a sizable pullback. This trade idea outlines an actionable mid-term short with clear entry, stop and target, plus the c…
<p>Palantir's recent drop has focused attention on headline volatility rather than the company's cash-generative contract base and long-duration customer relationships. This trade idea argues the selloff overstates near-term growth risk and offers a mid-term long entry with defined stop and targets.</p>
Leidos is trading near its 52-week low despite $17.2B in annual revenue, $1.86B in free cash flow and a healthy pipeline of defense work. Technicals show oversold conditions and short interest remains elevated, setting up a mid-term swing trade with defined risk and a clear catalyst roadmap.
Grab is no longer just a growth story — recent profitability and a slate of AI-enabled product launches make the Southeast Asian super-app a plausible cash-flow compounder. At a $14.4B market cap, the risk/reward looks attractive for a mid-term swing trade. Entry $3.54, stop $3.20, target $5.50 over ~45 trading days.
Frequency Electronics (FEIM) just pushed above its prior 52-week high on heavy volume and bullish technicals. A $71M backlog, a $20M authorized buyback, and investments in quantum sensing provide a credible growth narrative that could support a multiple expansion. That said, recent uneven revenue and negative free cash flow mean this is a tactical,…
Ranger Energy Services (RNGR) benefits from durable demand for high‑spec mobile rigs and complementary wireline and processing services. Strong Q2 2025 operating results and cash flow metrics give the company optionality and margin stability even if broader drilling activity softens. A mid‑term long trade targets upside toward the 52‑week high whil…
Agenus (AGEN) is a clinical-stage immuno-oncology company trading at a low market cap with active programs in botensilimab/balstilimab combos and several other immune-modulating assets. Recent clinical progress has created asymmetric upside on positive data or partnership news, but the company faces constrained liquidity and negative free cash flow…
